Inegy

Simvastatin/Ezetimibe, the active ingredient in Inegy, is a HMG‑CoA reductase inhibitor and cholesterol absorption inhibitor presented as an oral tablet for systemic use. It is indicated for lowering elevated cholesterol and triglyceride levels in adults with primary hyperlipidemia, mixed dyslipidemia, or familial hypercholesterolemia. The combination therapy targets both endogenous synthesis and dietary absorption of cholesterol, providing a synergistic effect that can improve lipid profiles when lifestyle measures alone are insufficient.

GNH USA supplies Inegy as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Inegy is used to treat disorders of lipid metabolism, primarily hypercholesterolemia and related conditions.

Hypercholesterolemia: reduces LDL‑cholesterol and total cholesterol levels. Mixed dyslipidemia: lowers LDL‑cholesterol while modestly decreasing triglycerides and raising HDL‑cholesterol. Primary hyperlipidemia (familial): provides significant LDL‑cholesterol reduction in patients with genetic lipid disorders.

Inegy may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Headache: mild to moderate intensity. - Myalgia or muscle pain: occasional discomfort. - Abdominal discomfort: mild stomach upset. - Nausea: occasional queasiness. - Diarrhea: loose stools. - Elevated liver enzymes: mild transaminase increase.

Serious or Rare Side Effects: - Rhabdomyolysis: severe muscle breakdown that can lead to renal failure. - Acute hepatitis or severe liver injury: marked elevation of liver enzymes with clinical symptoms. - Severe allergic reactions: rash, angioedema, or anaphylaxis requiring immediate medical attention.

Before initiating therapy, clinicians should consider several safety measures.

Liver function monitoring: assess baseline and periodic liver enzymes. Muscle symptom assessment: advise patients to report unexplained muscle pain or weakness. Drug interaction review: avoid concomitant use with strong CYP3A4 inhibitors. Contraindication in active liver disease: do not initiate in patients with hepatic impairment. Use caution in renal impairment: dose adjustment may be required. Store at room temperature: keep in original packaging, protect from moisture and light.

Inegy interacts with several medicines; some combinations should be avoided while others require careful monitoring.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., itraconazole, clarithromycin): increase plasma concentrations. - Gemfibrozil: markedly raises risk of myopathy. - Cyclosporine: elevates simvastatin levels. - HIV protease inhibitors (e.g., ritonavir): potentiate statin exposure. - High‑dose colchicine: risk of toxicity when combined.

Moderate Interactions (Monitor Closely): - Warfarin: may enhance anticoagulant effect; monitor INR. - Digoxin: possible increased serum levels. - Antacids (aluminum‑magnesium): may affect ezetimibe absorption.